IMMU-69. PROGNOSTIC IMPLICATION OF B-CELL INFILTRATE IN PATIENTS WITH GLIOBLASTOMA (GBM). (5th November 2018)
- Record Type:
- Journal Article
- Title:
- IMMU-69. PROGNOSTIC IMPLICATION OF B-CELL INFILTRATE IN PATIENTS WITH GLIOBLASTOMA (GBM). (5th November 2018)
- Main Title:
- IMMU-69. PROGNOSTIC IMPLICATION OF B-CELL INFILTRATE IN PATIENTS WITH GLIOBLASTOMA (GBM)
- Authors:
- Mauldin, Ileana
Jo, Jasmin
Erickson, Loren
Wages, Nolan
Slingluff, Craig
Lopes, M Beatriz
Fadul, Camilo E - Abstract:
- Abstract: BACKGROUND: One of the purported reasons of ineffectiveness of immunotherapy for GBM is the meager immune response in the tumor microenvironment. We have observed that GBM can harbor dense B-cell infiltrate, but their prevalence and function is unknown. Pre-clinical studies have shown that B-cells can act as antigen-presenting cells which can stimulate T-cell proliferation; however, B-cells can also downregulate effector T-cells by secreting immunosuppressive cytokines including IL-10. Our study aims to determine the roles of B-cells in GBM and their association with patient outcomes. METHODS: Multiplexed immunohistochemistry, imaging and quantitation was performed on primary GBM samples obtained between 1/2008-8/2015. Intratumoral CD20 + B-cells and CD8 + T-cells infiltrate were enumerated from 3 serial GBM sections. Relevant prognostic clinical and molecular variables were reviewed. We also analyzed the association of MS4A1 gene encoding B-cell antigen CD20 with survival from the TCGA. RESULTS: We observed an average infiltrate of 5.5 CD20 + cells/mm 2 and 36.7 CD8 + cells/mm 2 tumor. B-cells were stratified into CD20 low (12 patients) and CD20 high groups (36 patients) with 0.24 B-cells/mm 2 cut off. Kaplan-Meier analyses indicated that the CD20 low group had better overall survival (OS) than the CD20 high cohort (31.7 versus 18.7 months; p=0.02), while a trend toward improved survival was observed with high CD8 + T-cell infiltration (p=0.06). Cox proportionalAbstract: BACKGROUND: One of the purported reasons of ineffectiveness of immunotherapy for GBM is the meager immune response in the tumor microenvironment. We have observed that GBM can harbor dense B-cell infiltrate, but their prevalence and function is unknown. Pre-clinical studies have shown that B-cells can act as antigen-presenting cells which can stimulate T-cell proliferation; however, B-cells can also downregulate effector T-cells by secreting immunosuppressive cytokines including IL-10. Our study aims to determine the roles of B-cells in GBM and their association with patient outcomes. METHODS: Multiplexed immunohistochemistry, imaging and quantitation was performed on primary GBM samples obtained between 1/2008-8/2015. Intratumoral CD20 + B-cells and CD8 + T-cells infiltrate were enumerated from 3 serial GBM sections. Relevant prognostic clinical and molecular variables were reviewed. We also analyzed the association of MS4A1 gene encoding B-cell antigen CD20 with survival from the TCGA. RESULTS: We observed an average infiltrate of 5.5 CD20 + cells/mm 2 and 36.7 CD8 + cells/mm 2 tumor. B-cells were stratified into CD20 low (12 patients) and CD20 high groups (36 patients) with 0.24 B-cells/mm 2 cut off. Kaplan-Meier analyses indicated that the CD20 low group had better overall survival (OS) than the CD20 high cohort (31.7 versus 18.7 months; p=0.02), while a trend toward improved survival was observed with high CD8 + T-cell infiltration (p=0.06). Cox proportional hazard demonstrated an association between decreased OS and CD20 high cohort (HR=2.8, p=0.03), but no significance seen between CD8 + infiltration and OS (p=0.16). A positive correlation was detected between CD8 + and CD20 + density (p CONCLUSIONS: Our results suggest that B-cell infiltrate carries an inverse correlation with survival. We hypothesize that CD20 + B-cells may be regulatory B-cells, limiting immune activation in GBM. Further studies are underway to understand the role of B-cells in the GBM microenvironment. … (more)
- Is Part Of:
- Neuro-oncology. Volume 20(2018)Supplement 6
- Journal:
- Neuro-oncology
- Issue:
- Volume 20(2018)Supplement 6
- Issue Display:
- Volume 20, Issue 6 (2018)
- Year:
- 2018
- Volume:
- 20
- Issue:
- 6
- Issue Sort Value:
- 2018-0020-0006-0000
- Page Start:
- vi137
- Page End:
- vi137
- Publication Date:
- 2018-11-05
- Subjects:
- Brain Neoplasms -- Periodicals
Brain -- Tumors -- Periodicals
Brain -- Cancer -- Periodicals
Nervous system -- Cancer -- Periodicals
616.99481 - Journal URLs:
- http://neuro-oncology.dukejournals.org/ ↗
http://neuro-oncology.oxfordjournals.org/ ↗
http://www.oxfordjournals.org/content?genre=journal&issn=1522-8517 ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/neuonc/noy148.572 ↗
- Languages:
- English
- ISSNs:
- 1522-8517
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6081.288000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 12325.xml